Anti-LPA antibody: Phase Ia started

Lpath began a double-blind, placebo-controlled, dose-escalation, U.S. Phase Ia trial to evaluate single doses of 0.5, 1, 3, 10 and 20 mg/kg IV Lpathomab in about 36 healthy volunteers. ...